Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.779252
Title: Novel AAV engineering technology : identification of improved AAV variants for gene addition and genome engineering in primary human cells
Author: Cabanes Creus, Martí
ISNI:       0000 0004 7964 9485
Awarding Body: UCL (University College London)
Current Institution: University College London (University of London)
Date of Award: 2019
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
Vectors based on Adeno-associated virus (AAV) are currently the most used gene transfer tools in the human gene therapy field. In order to overcome some of the intrinsic limitations of AAVs, lots of efforts have been put around AAV capsid engineering, with the ultimate goal of developing new recombinant serotypes with novel properties such as enhanced tropism for specific human cell types, increased manufacturability and decreased human seroreactivity. The work described in this thesis focus in an exhaustive revision of the process of new vector development. Firstly, we adapted new cloning strategies and bacterial selection on the AAV library construction field, allowing the generation of larger libraries, and reducing the time and effort needed for assembly. Secondly, we describe a new method based on codon optimization that when applied to AAV DNA-family shuffling overcomes the limitation encountered by phylogenetically distant serotypes to contribute on chimeric clones due to lack of DNA homology to other parental serotypes. This allowed to increase the complexity of the generated libraries. Thirdly, we generated and describe here a new high-throughput AAV vector selection platform to perform selection based on functional transduction (transgene expression).Briefly, we substituted the rep gene present on the AAV genome for a GFP reporter cassette under the control of a promoter of choice, and kept the cap library. This allows to transduce the cells of interest, FACS-sort the GFP positive cells and recover the capsid genes that encoded capsids that led to efficient functional transduction using PCR. Finally, we applied those three new AAV engineering technologies to develop novel capsids with improved tropism for primary human CD34+ cells, T-cells and hepatocytes.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.779252  DOI: Not available
Share: